fda warning letter compounding semaglutide october 2025 letters alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA warns consumers not to – Compounding of GLP-1 Drugs |

Key Takeaways Nutrition strategies can complement GLP-1 medications by improving adherence, reducing hunger, and supporting more sustainable weight loss outcomes

Even small changes in how much food you eat or how fast glucose enters your bloodstream can lead to mismatches between your insulin delivery and your actual needs

BPC-157 is supplied as a pre-mixed solution in a sealed vial no reconstitution step is required

Ohio to end GLP-1 drug weight loss coverage for state workers COLUMBUS, Ohio (WSYX) The Ohio Department of Administrative Services announced that coverage for GLP-1 drugs for weight loss, including Ozempic and Mounjaro, will end for state employees on July 1, 2025

Here's what the program covers, who qualifies, and how to use it if you or a family member on Medicare is interested

Jul 2016;13(7):788-795